---
title: "Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration. Clinical evidence covers ARCHER II, ARCHER, AiiM OLE, ANX007-GLA-02, and ANX007-GLA-01. 531 evidence topics quoted from 167 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Vonaprument

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of Geographic atrophy secondary to age-related macular degeneration

<a id="topic-1.1.1-1"></a>

##### Summary: definition, epidemiology, and natural history

Geographic atrophy (GA) is “the advanced form of non-neovascular AMD”, characterized by “confluent atrophy of photoreceptors, RPE and choriocapillaris” and associated with scotoma. Loss of visual function from GA “is considered irreversible and usually bilateral”, with half of patients developing GA in both eyes within 7 years of the initial diagnosis. The most important risk factors for GA are increasing age and family history; cigarette smoking is the modifiable risk factor most consistently identified for advanced AMD, and the estimated heritability of late-stage AMD is approximately 71%.

Published studies estimate that approximately 1 million people in the United States have GA in at least 1 eye. In a claims analysis with denominators of 2,175,803 (2018) to 2,905,366 (2021) patients, the annual prevalence of GA was 0.56% in 2018, 0.55% in 2019, 0.48% in 2020, and 0.51% in 2021. Prevalence was 0.95% to 1.11% among individuals aged 75 years and older and 0.15% to 0.18% among those younger than 75 years, and 0.61% to 0.71% among individuals classified as White race and 0.09% to 0.11% among those classified as Black race. Adding 12 months to the ascertainment window raised annual prevalence to 0.85% (2018), 0.83% (2019), 0.77% (2020), and 0.74% (2021), and the authors state that the lower prevalence in claims data relative to other studies “warrants careful consideration”. Annual incidence of GA in American White adults aged 50 years and older, estimated from prevalence, was 1.9 per 1000, corresponding to approximately 160 000 new cases per year (95% credible interval 107 000 to 234 000); the rate was 4.3 per 1000 at age 65 years and older and 10.9 per 1000 at age 80 years and older.

In a pooled analysis of 39 studies, the 8 studies that reported GA and neovascular subtypes gave an overall GA prevalence of 0.44% (95% credible interval 0.15% to 1.36%), which was higher in Europeans (1.11%) than in Africans (0.14%), Asians (0.21%), and Hispanics (0.16%). An estimated 166 307 individuals in Nordic countries had GA in 2023, a number projected to reach 277 893 in 2050.

GA lesions enlarge over time. The pooled mean growth rate was 1.66 mm2/year across 23 studies (3,078 patients), and larger baseline lesions were associated with faster growth. In one cohort, the median time from any GA diagnosis to central GA was 2.5 years, and visual acuity decreased by 3.7 letters at first documentation of central GA and by 22 letters at year 5; the median time to bilateral GA was 7 years. In another cohort, 32% of eyes with noncentral GA progressed to central GA by 2 years and 57% by 4 years, best-corrected visual acuity (BCVA) declined by 2.3 letters per year overall, and the 4-year risk of subsequent neovascular AMD in eyes with incident GA was 29%. In the Proxima A study of participants with bilateral GA, the adjusted mean change in study eye BCVA from baseline to 24 months was −13.88 letters. In claims data, 479 of 4,781 individuals (10.2%) with GA without subfoveal involvement at index progressed to GA with subfoveal involvement during 12 months of follow-up. Among participants with GA followed for a median of 6.8 years, those with total GA area in the highest quartile had a higher adjusted risk of all-cause mortality than those in the lowest quartile (hazard ratio [HR] 3.42; 95% CI 1.32 to 8.86).

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf); [Fleckenstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12878645/); [Boyer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5424580/); [Bakri et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10408405/); [Fleckenstein et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12935482/); [Saundankar et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695844/); [Rudnicka et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25857680/); [Wong et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25104651/); [Vangsted et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37680141/); [Wang and Ying (2021)](https://pubmed.ncbi.nlm.nih.gov/32721951/); [Lindblad et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6500457/); [Keenan et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6246813/); [Holekamp et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32081489/); [Saundankar et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695847/); [Ahluwalia et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33742280/)

<a id="topic-1.1.1-2"></a>

##### Summary: humanistic burden and long-term morbidity

GA can produce “dense, irreversible scotomas in the visual field” and deficits in reading, night vision, and dark adaptation, while the initial decline in visual acuity “may be relatively minor if the fovea is spared”. In one study, half of eyes with GA had maximum reading rates below 100 words per minute. In a study in the United Kingdom, Germany, Ireland, and Canada, the mean NEI VFQ-25 composite score was 53.1 points in 137 patients with GA and 84.5 points in 52 patients without GA (adjusted difference −28.82; P<0.001). In that study, 18% of patients with GA were registered as legally blind or going through the assessment process for registration, and 27.6% of patients with GA were currently driving compared with 69.2% of patients without GA. In a survey of patients with GA, nearly 86% (n = 88) did not currently drive, 67% and 68% reported moderate to extreme difficulty reading a newspaper and small print, respectively, 56% named losing their independence as their biggest concern, and 51% worried about their eyesight most or all the time. Charles Bonnet syndrome was present in 25 of 120 patients with GA (20.8%). Among 153 participants with treatment-naive GA at 9 UK National Health Service centers, median EQ-5D health index scores were 0.75 (27 participants) and 0.74 (126 participants) in the groups that rated intravitreal injections unacceptable and acceptable, respectively.

GA is responsible for approximately 20% of legal blindness in the United States. In claims data, irreversible blindness developed in 173 individuals (3.6%) with GA without subfoveal involvement, 312 (6.6%) with subfoveal involvement, and 51 (0.5%) without GA (HR 6.77 for GA without and 12.59 for GA with subfoveal involvement). In one cohort, 71.1% of patients had visual acuity in the better-seeing eye that would have made them ineligible to drive at first record of GA; over time, 16% became legally blind (median time to outcome, 6.2 years) and 66.7% became ineligible to drive (median time to outcome, 1.6 years). Across the Clinformatics, MarketScan, and PharMetrics databases, patients with GA had higher risks than controls of falls (RR 1.16 to 1.36) and fractures (RR 1.17 to 1.29) in the 4 years after the index date, and of nursing home or assisted living admissions (RR 1.06 to 1.28). In a matched claims cohort, the incidence of new-onset depression was 86.6 per 1,000 person-years with GA and 77.3 per 1,000 person-years without GA (P = 0.004), and approximately 20% of patients with GA had evidence of an anxiety disorder during follow-up.

Source: [Holz et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24433969/); [Sunness et al. (1997)](https://pubmed.ncbi.nlm.nih.gov/9331210/); [Patel et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6955611/); [Bakri et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11348935/); [Eriksen et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11736733/); [Dinah et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12464851/); [Saundankar et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695847/); [Chakravarthy et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29366564/); [Hu et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12006262/)

<a id="topic-1.1.1-3"></a>

##### Summary: economic burden and healthcare resource utilization

In a cost study of 18,119 patients with GA only, 2,285 with GA and visual impairment, 1,716 with GA and blindness, and 72,476 patients without GA (costs in 2021 US dollars), annual all-cause total healthcare costs were $26,696 for patients with GA only and $25,524 for patients without GA, a difference of $1,171 (95% CI 204 to 2,138; P=0.018) driven primarily by outpatient visit costs. Patients with GA and visual impairment spent an average of $5,096 more per year, and patients with GA and blindness $9,952 more per year, than patients with GA only. In that study, patients with GA had higher rates of all-cause hospitalizations (RR 1.08) and outpatient visits (RR 1.08) than patients without GA. Across the Clinformatics, MarketScan, and PharMetrics databases, patients with GA had higher risks than controls of hospitalization (RR 1.18 to 1.27) and emergency department visits (RR 1.18 to 1.21). A matched claims cohort found no statistically significant difference in inpatient stays or emergency department visits, and a higher number of outpatient visits with GA (mean 18.3 vs 16.7). In a study of 28,773 GA cases, disease-specific costs ranged from $56 to $110. In closed-claims cohorts of 5827 patients, visual acuity impairment was associated with an increase of more than 26% in total cost of care by year 2; among the severity categories, the adjusted cost ratio reached statistical significance for moderate impairment alone (1.37; 95% CI 1.00 to 1.86; P = .045).

A systematic review reported a mean total first-year cost after diagnosis of US $11,672 per patient with GA to the health-care system and a mean cost to the patient of $2863 (2020 USD) in a US retrospective study of 14,421 patients, and identified only 7 studies of GA resource use and costs. A cost-of-illness model for the United States estimated a total annual cost of €39 251 per person with GA, comprising direct medical costs of €327 (0.8%), indirect medical costs of €12 744 (32.5%), well-being costs of €11 948 (30.4%), and productivity costs of €14 232 (36.3%); the authors attribute the lower direct medical costs for GA than for neovascular AMD to the absence of GA treatment options at the time of the research, and note that the patient survey samples were relatively small. In the United Kingdom, Germany, Ireland, and Canada, the annualized average direct and indirect ophthalmic cost was €2006 per patient with GA, of which diagnostic tests and procedures accounted for €1071.

Source: [Sarda et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11559221/); [Hu et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12006262/); [Saundankar et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695847/); [Kim et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8236262/); [Borkar et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13226300/); [Sarda et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8667751/); [Paudel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12316190/); [Patel et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6955611/)

<a id="topic-1.1.1-4"></a>

##### Summary: burden on caregivers and families

In a survey of patients with GA and their caregivers, 83% of caregivers drove patients to their eye appointments for GA and 76% to other medical appointments, caregivers spent a median of 10 hours per week (interquartile range 5 to 25) on household tasks the patients could otherwise have performed independently, and 81% lived with the person they cared for. Forty-one percent of caregivers had a change in employment status after becoming a caregiver; of these, 50% were unable to work due to caregiving, 29% worked fewer hours, and 12% retired early. Patients and caregivers used their own money for extra lighting, eyeglasses, and reading devices, and 44% of patients and 37% of caregivers were concerned or very concerned about the effect of GA on their finances in the future. The mean Zarit Burden Interview total score was 24.8 (SD 18.7) on a scale of 0 to 88, and correlation coefficients between patient NEI VFQ-39 scores and caregiver burden ranged from −0.63 to −0.21. In the United States cost-of-illness estimate, 12% of the productivity cost of GA was attributable to the impact on caregivers. A systematic review identified “very little information” on the humanistic effect of GA on caregivers.

Source: [Bakri et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11348935/); [Paudel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12316190/); [Sarda et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8667751/)

<a id="heading-1.1.2"></a>

#### 1.1.2 Vonaprument Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary: ARCHER II pivotal phase 3 trial (design and status)

- Design: ARCHER II is a phase 3, multicenter, randomized, parallel-group, double-masked, sham-controlled trial. It enrolled 659 participants, randomized 2:1 to vonaprument 5.0 mg per eye or a sham procedure, each given monthly for 24 months, with treatment masked through 24 months. The phase 3 dose of 5 mg is administered in 25 microliters; the phase 2 ARCHER trial used 5 mg in 100 microliters. The registry lists 132 locations, and participants were enrolled from North America (55%), Europe (43%), and Australia and New Zealand (2%).
- Eligibility and baseline: participants were at least 50 years of age, with a GA lesion area of 2.5 to 17.5 mm² and BCVA of 45 to 83 ETDRS letters (20/25 to 20/100 Snellen equivalent). The sponsor states that individuals with baseline BCVA below 45 letters were not enrolled “due to very low incidence of BCVA 15-letter loss in ARCHER”. In pooled baseline data, mean age was 78.4 years, mean BCVA was 65.8 letters, and 54.8% of participants had subfoveal lesions.
- Endpoints: the two primary endpoints are the proportion of participants with BCVA loss of 15 or more letters from baseline at any two consecutive visits through Month 15 and through Month 24. The Month 24 endpoint was added in August 2026, when all eligible participants had received at least 12 months of masked treatment, with alpha allocated between Month 15 (the majority) and Month 24. Secondary endpoints include time to confirmed BCVA ≥15-letter loss, the proportion with LLVA ≥15-letter loss, change from baseline in the area of total ellipsoid zone loss, and the incidence and severity of ocular and systemic treatment-emergent adverse events and adverse events of special interest. The design announced in 2023 planned approximately 400 participants randomized 1:1, with the primary endpoint assessed through 12 months.
- Regulatory basis: the sponsor reports alignment with the FDA and the EMA on BCVA ≥15-letter loss as the primary outcome measure, and states that the FDA “has not required Annexon to study the slowing of lesion growth”. The single study will be analyzed for the EU filing and, for the U.S. filing, as two pre-defined sub-studies of about 330 participants each, “in accordance with the FDA’s two-trial recommendation”.
- Status: as of the sponsor’s third-quarter 2026 results release, ARCHER II has reported no efficacy or safety results. All eligible participants had received at least 15 months of treatment, and retention was 90%. The sponsor expects an independent Data Monitoring Committee to assess the Month 15 primary endpoint in the fourth quarter of 2026, sub-study results in the first quarter of 2027 if the endpoint is met, and study completion with the Month 24 analyses in the third quarter of 2027. The Form 10-Q states that “there is no assurance that either timepoint will show a statistically significant treatment effect”. After Month 24, participants may receive monthly vonaprument in an open-label extension study.

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816); [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00); [Eichenbaum (2025)](https://annexonbio.com/wp-content/uploads/2025/07/Eichenbaum-ASRS-2025-Design-and-Rationale-ARCHER-II.pdf); [Abbey (2026)](https://annexonbio.com/wp-content/uploads/2026/09/910_Friday_Abbey_Baseline-Characteristics-of-Participants-in-the-Phase-3-ARCHER-II-Trial-in-Dry-AMD-With-GA-FINAL-25Sept26.pdf); [Gallego-Pinazo (2026)](https://annexonbio.com/wp-content/uploads/2026/10/Gallego-Pinazo-Euretina.pdf); [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c); [EURETINA Congress (2024)](https://annexonbio.com/wp-content/uploads/2024/09/Euretina-symposium.pdf); [Annexon Biosciences ARCHER II registrational program press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-outlines-global-registrational-program-anx007-geographic); [Annexon Biosciences ARCHER II update press release (2024)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-provides-update-archer-ii-global-registrational-program); [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy); [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b); [Annexon Biosciences third-quarter 2026 results press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-third-quarter-2026-financial-results-business); [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

<a id="topic-1.1.2-2"></a>

##### Summary: ARCHER phase 2 efficacy

ARCHER was a randomized, double-masked, sham-controlled phase 2 trial that enrolled 270 participants with GA, randomized to intravitreal vonaprument 5 mg monthly (n=89), 5 mg every other month (n=92), or sham monthly or every other month (pooled n=89) for 12 months, followed by a 6-month off-treatment period. The results are available from the registry record and from sponsor press releases, filings, and congress presentations; an independent systematic review published in 2026 states that “no peer-reviewed publications reporting their clinical results are available to date” and excluded them from its evidence synthesis.

- Primary endpoint (not met): the rate of change (slope) in GA lesion area by fundus autofluorescence from baseline to month 12 did not reach statistical significance. In the registry analysis, which included non-subfoveal participants only, the slope was 1.9902 mm²/year with monthly dosing (38 participants), 2.1575 mm²/year with every-other-month dosing (43), 2.0837 mm²/year for the pooled vonaprument groups (81), and 1.9019 mm²/year with sham (45). The sponsor reported reductions in lesion growth of 6.2% with monthly dosing (p=0.526), 1.3% with every-other-month dosing (p=0.896), and 3.7% for the pooled groups (p=0.673).
- Confirmed BCVA ≥15-letter loss (prespecified secondary analysis): the registry reports 4 events among 89 participants with monthly dosing, 8 among 92 with every-other-month dosing, and 15 among 89 with sham, defining confirmed loss as loss “observed for 2 consecutive visits”. The 2023 topline release used a definition that also counted “a loss at the end of the 12-month treatment period” and reported 5 of 89 participants (5.6%), 10 of 92 (10.9%), and 19 of 89 (21.3%), with p=0.0021 for monthly and p=0.055 for every-other-month dosing. The 2026 company presentation reports two definitions: loss confirmed “through month 12 or at last study visit” in 5 of 89 (5.6%), 9 of 92 (9.8%), and 19 of 89 (21.3%), with nominal p=0.0021 and p=0.032; and loss with the “month 12 event confirmed at month 15” in 4 of 89 (4.5%), 8 of 92 (8.7%), and 15 of 89 (16.9%), with nominal p=0.0076 and p=0.0994. The counts under the second definition equal the registry counts. The presentation labels these p-values as nominal, from a chi-square test in the ITT population, and the Form 10-K describes the monthly result as “nominally statistically significant”.
- Time to confirmed BCVA ≥15-letter loss (Kaplan-Meier analysis, nominal log-rank p-values): the 2026 presentation reports a hazard ratio of 0.272 (CI 0.090 to 0.819; nominal p=0.0119) with monthly dosing and 0.504 (CI 0.214 to 1.189; nominal p=0.1098) with every-other-month dosing. A 2024 presentation reported the same hazard ratios with p=0.0098 and p=0.0788, and the 2023 topline release reported risk reductions of 72% (p=0.006) and 48% (p=0.064).
- Mean change in BCVA at month 12 (prespecified visual function measure): -1.7 letters with monthly dosing, -2.6 letters with every-other-month dosing, and -4.1 letters with sham, with nominal p=0.1904 and p=0.3977 from a mixed model for repeated measures.
- Low-luminance visual acuity (change from baseline was a prespecified visual function measure): the registry reports LLVA ≥15-letter loss events in 6 of 79, 8 of 85, and 16 of 79 participants (monthly, every other month, sham). The 2023 topline release reported 8 of 79 (10.1%), 10 of 85 (11.8%), and 16 of 79 (20.3%), with p=0.076 and p=0.14, described as a “non-significant trend”. The 2026 presentation reports 6 of 79 (7.6%), 8 of 85 (9.4%), and 16 of 79 (20.3%), with nominal p=0.0216 and p=0.0497. Mean change in LLVA at month 12 was -1.4, -2.8, and -4.8 letters, with nominal p=0.0592 and p=0.2664.
- Ellipsoid zone loss (prespecified structural analysis, nominal p-values, Spectralis OCT subpopulation): compared with sham, pooled vonaprument was associated with a 27% decrease in total ellipsoid zone loss across the macula (107 vonaprument and 67 sham participants; nominal p=0.0457), a 48% decrease within the central 2.0 mm (nominal p=0.0218), and a 59% decrease within the central 1.5 mm (nominal p=0.0319).
- Other loss thresholds (nominal p-values, 2026 presentation): loss of 10 or more letters occurred in 15.7% with monthly dosing, 20.7% with every-other-month dosing, and 25.8% with sham (nominal p=0.096 and p=0.408); loss of 20 or more letters occurred in 4.5%, 6.5%, and 16.9% (nominal p=0.008 and p=0.030).
- Subgroups by lesion location: the topline combined analysis stratified by foveal and non-foveal lesions reported p=0.0019 for monthly and p=0.0439 for every-other-month dosing. Within subgroups (final data, nominal chi-square p-values), BCVA ≥15-letter loss among participants with foveal lesions occurred in 3 of 51 (5.9%) with monthly dosing (nominal p=.0088) and 8 of 49 (16.3%) with every-other-month dosing (nominal p=.3003), against 11 of 44 (25.0%) with sham; among participants with non-foveal lesions it occurred in 2 of 38 (5.3%; nominal p=.0810) and 1 of 43 (2.3%; nominal p=.0168), against 8 of 45 (17.8%).
- Subfoveal lesions (post hoc analysis): BCVA ≥15-letter loss occurred in 3 of 51 (5.9%) with monthly dosing (nominal p=.0172) and 7 of 49 (14.3%) with every-other-month dosing (nominal p=.2930), against 10 of 44 (22.7%) with sham; the hazard ratio with monthly dosing was 0.242 (CI 0.067 to 0.881; nominal p=.0204).
- Baseline low-luminance visual deficit and less advanced disease: the topline combined analysis stratified by baseline LLVD below 30 or 30 and above reported p=0.0016 for monthly and p=0.029 for every-other-month dosing. In additional analyses, the sponsor reports a larger response in eyes with lower LLVD, smaller lesions, and more remaining ellipsoid zone.
- Off-treatment period: in a preliminary 6-month off-treatment analysis, the rate of BCVA ≥15-letter loss in the treated groups increased to parallel that of sham (“>1.6% per month”).
- Number needed to treat (sponsor calculation from the prespecified secondary analysis): “1 / (21.3 – 5.6) * 100= 6.4”, reported as 7 for monthly dosing to avoid BCVA ≥15-letter loss, with 10 for loss of 10 or more letters and 8 for loss of 20 or more letters.

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results); [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic); [Annexon Biosciences ASRS 2023 press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-presents-archer-trial-results-asrs-2023-highlighting); [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm); [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c); [Pearlman (2024)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-Pearlman-FINAL.pdf); [Vakharia (2025)](https://annexonbio.com/wp-content/uploads/2025/05/Vakharia-RWC-2025-NNT.pdf); [Khurana (2025)](https://annexonbio.com/wp-content/uploads/2025/02/Khurana-MacSoc-2025-Central-Subdomains-.pdf); [Stanga et al. (2024)](https://annexonbio.com/wp-content/uploads/2024/12/Stanga-FloRetina-Final-Dec24.pdf); [Goren Fein et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/J-Goren-Fein-RWC-Poster-FINAL-11May26.pdf); [Barakat (2026)](https://annexonbio.com/wp-content/uploads/2026/09/913_Friday_Barakat_-Vision-Outcomes-in-Eyes-With-Subfoveal-RPE-Lesions-in-Geographic-Atrophy-A-Post-Hoc-Analysis-of-the-Phase-2-ARCHER-Trial-FINAL-25Sept26.pdf); [Fernández-Muro et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13708414/)

<a id="topic-1.1.2-3"></a>

##### Summary: safety

- ARCHER overall (12-month treatment period, registry): treatment-emergent adverse events occurred in 65 of 89 participants with monthly dosing, 68 of 92 with every-other-month dosing, and 68 of 89 with sham. Serious adverse events occurred in 21 of 89 (23.60%), 16 of 92 (17.39%), and 16 of 89 (17.98%), and all-cause mortality was 2 of 89 (2.25%), 3 of 92 (3.26%), and 2 of 89 (2.25%). Treatment was discontinued by 13 (14.6%), 11 (12.0%), and 10 (11.2%) participants.
- Endophthalmitis: serious endophthalmitis occurred in 1 of 89 (1.12%) with monthly dosing, 2 of 92 (2.17%) with every-other-month dosing, and 0 of 89 with sham. The sponsor determined the 3 events to be related to the intravitreal injection procedure and “not related to treatment”.
- Intraocular inflammation and vascular occlusion: intraocular inflammation occurred in 2 participants (2.2%) with monthly dosing, 1 (1.1%) with every-other-month dosing, and none with sham; the topline release described 3 serious events of intraocular inflammation “suspected of being treatment-related”, not associated with retinal vasculitis. The iritis resolved with topical steroids in 2 days and the vitritis in 9 days. One retinal vascular occlusion (1.1%) occurred with every-other-month dosing, described as “Isolated cilioretinal artery occlusion; no vasculitis confirmed by DSMC and reading center”.
- Retinal vasculitis and ischemic optic neuropathy: no events were reported in any arm.
- Choroidal neovascularization: 3 participants (3.4%) with sham, 4 (4.5%) with monthly dosing, and 4 (4.3%) with every-other-month dosing.
- Other events: non-serious conjunctival haemorrhage occurred in 7.87%, 6.52%, and 3.37% of participants (monthly, every other month, sham). Serious atrial fibrillation occurred in 2 of 89 (2.25%), 4 of 92 (4.35%), and 0 of 89, and serious pneumonia in 3 of 89 (3.37%), 2 of 92 (2.17%), and 0 of 89.
- ARCHER II: no safety results have been reported.
- Phase 1 glaucoma studies (participants with primary open-angle glaucoma; 5 mg given in 100 μL): in the open-label single-dose phase Ia study (1 mg, 2.5 mg, or 5.0 mg; 9 participants), all 9 participants (100.0%) had a treatment-emergent adverse event, most often conjunctival hyperemia (8; 88.9%); all adverse events were mild and resolved, no dose-limiting toxicities were observed, no anti-drug antibodies were detected, serum unbound drug was not detected, and serum unbound C1q was unchanged. In the double-masked, sham-controlled phase Ib study (2 injections 4 weeks apart; 17 participants treated), no serious, severe, or fatal adverse events were reported, the 6 treatment-emergent adverse events were mild, intraocular pressure returned to 21 mm Hg or lower within 45 minutes in all participants, no systemic pharmacokinetic or pharmacodynamic changes were observed, and low-level anti-drug antibody positivity was detected in 7 participants, including 1 in the sham group.

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results); [EURETINA Congress (2024)](https://annexonbio.com/wp-content/uploads/2024/09/Euretina-symposium.pdf); [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic); [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c); [Annexon Biosciences third-quarter 2026 results press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-third-quarter-2026-financial-results-business); [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-1.1.2-4"></a>

##### Summary: comparison with approved complement inhibitors

- No head-to-head data: no trial has compared vonaprument with pegcetacoplan or avacincaptad pegol. In 2023 the sponsor planned ARROW, a phase 3 trial of approximately 500 participants comparing monthly vonaprument with pegcetacoplan as an injection comparator; in 2025 it stated that it “no longer plans to conduct a second injection-controlled head-to-head Phase 3 trial”. ARCHER II compares vonaprument with a sham procedure.
- Dosing: pegcetacoplan is labeled at 15 mg (0.1 mL) by intravitreal injection once every 25 to 60 days, and avacincaptad pegol at 2 mg (0.1 mL) once monthly; ARCHER II gives vonaprument 5 mg in 25 microliters monthly.
- Endpoints: pegcetacoplan and avacincaptad pegol were approved on a reduction in the rate of GA expansion, and a 2024 review states that functional data from two phase 3 trials for each drug “demonstrated no visual benefit to patients in the treatment groups”. ARCHER II uses BCVA ≥15-letter loss as its primary endpoint, and in phase 2 vonaprument did not significantly reduce lesion growth. The sponsor states that “Protection of RPE has not resulted in preservation of vision” with C3 and C5 inhibitors, and that the two approved products “may pose competition for vonaprument, if approved”.
- Independent appraisal: a 2026 systematic review excluded C1q inhibition from its evidence synthesis because its results “are not yet supported by peer-reviewed publications”.

Source: [Annexon Biosciences ARCHER II registrational program press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-outlines-global-registrational-program-anx007-geographic); [Annexon Biosciences fourth-quarter 2024 results press release (2025)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-fourth-quarter-and-year-end-2024-financial); [Apellis Pharmaceuticals Syfovre prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217171Orig1s003lbl.pdf); [Astellas Pharma US Izervay prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217225s004lbl.pdf); [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c); [Csaky et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11162935/); [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm); [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic); [Fernández-Muro et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13708414/)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Vonaprument

<a id="topic-1.1.3-1"></a>

##### Summary: price and economic evidence status

Vonaprument is investigational, and the sponsor states that it does not “have any products approved for sale”. No price, wholesale acquisition cost, average sales price, or HCPCS code for vonaprument has been published, and no cost-effectiveness analysis, budget impact model, or health technology assessment of vonaprument was identified. The phase 3 ARCHER II trial, ongoing in 659 participants, tests monthly vonaprument 5.0 mg per eye. As of the latest source, the sponsor's third-quarter 2026 results press release, ARCHER II had reported no results: an independent Data Monitoring Committee “will assess the ARCHER II single study Month 15 primary endpoint in the fourth quarter of 2026”, with results of the two pre-specified sub-studies “anticipated in the first quarter of 2027” if the endpoint is met, and ARCHER II completion “expected in the third quarter of 2027”. The single study is to be analyzed for an EU filing and the two sub-studies for a U.S. filing.

The sponsor states that it has “established a small commercial organization and have not established distribution capabilities”, that it has “not yet engaged any manufacturers for the commercial supply” of its product candidates, and that there is no assurance that a product “will be considered cost-effective by third-party payors”.

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm); [Annexon Biosciences third-quarter 2026 results press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-third-quarter-2026-financial-results-business); [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b); [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-1.1.3-2"></a>

##### Summary: company estimate of the treated population

In a statement that begins “Based on market reports”, the sponsor estimates that approximately 75,000 patients in the United States are actively treated with available therapies, about 10% of the 800,000 people diagnosed with geographic atrophy or under the care of retina specialists and about 5% of a U.S. population with geographic atrophy of 1.5 million. The sponsor's Form 10-K gives a different prevalence figure, stating that geographic atrophy affects “more than an estimated one million people in the United States and eight million people worldwide”.

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b); [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-1.1.3-3"></a>

##### Summary: comparator costs and utilization

- Medicare Part B payment limits for October to December 2026 were $135.267 per 1 mg billing unit of pegcetacoplan (Syfovre, J2781), an “AMP-based payment limit”, and $100.563 per 0.1 mg billing unit of avacincaptad pegol (Izervay, J2782).
- At launch in 2023, the list price was $2,190 per vial for Syfovre and $2,100 per vial for Izervay.
- The national non-facility Medicare payment for an intravitreal injection (CPT 67028) was $114.23 in 2026, an increase of 4.79% from $109.01 in 2025.
- Medicare Part B spending on pegcetacoplan was $76,651,580.03 for 17,414 beneficiaries in 2023, $403,855,394.80 for 29,338 beneficiaries (148,576 claims) in 2024, $451,069,360.05 for 32,021 beneficiaries (168,366 claims) in 2025, and $109,568,082.68 for 24,179 beneficiaries (41,654 claims) in the first quarter of 2026.
- Medicare Part B spending on avacincaptad pegol was $190,365,232.80 for 18,308 beneficiaries (73,172 claims) in 2024, $364,934,587.10 for 27,497 beneficiaries (140,741 claims) in 2025, and $105,232,261.84 for 23,315 beneficiaries (41,264 claims) in the first quarter of 2026; the annual dataset reports no 2023 values for this product.

Source: [CMS Medicare Part B Payment Limit File (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip); [Fidler (2023)](https://www.biopharmadive.com/news/astellas-iveric-fda-approval-geographic-atrophy-izervay/690052/); [American Academy of Ophthalmology Medicare payment comparison (2026)](https://assets.aao.org/2026-07/Office%20-%202025%20vs%202026%20Medicare%20Pay%20Final%20Rule.pdf); [CMS Medicare Part B Spending by Drug (2026)](https://data.cms.gov/data-api/v1/dataset/76a714ad-3a2c-43ac-b76d-9dadf8f7d890/data?filter%5Bc%5D%5Bcondition%5D%5Bpath%5D=HCPCS_Cd&filter%5Bc%5D%5Bcondition%5D%5Boperator%5D=IN&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2781&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2782); [CMS Medicare Quarterly Part B Spending by Drug (2026)](https://data.cms.gov/data-api/v1/dataset/bf6a5b3b-31ee-4abb-b1ad-2607a1e7510a/data?filter%5Bc%5D%5Bcondition%5D%5Bpath%5D=HCPCS_Cd&filter%5Bc%5D%5Bcondition%5D%5Boperator%5D=IN&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2781&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2782)

<a id="topic-1.1.3-4"></a>

##### Summary: published comparator economic evaluations

A U.S. analysis based on 2022 Medicare reimbursement data, with outcomes extrapolated from the DERBY and OAKS trials, reported 2-year costs to treat geographic atrophy with pegcetacoplan of $70,000 with every-month (EM) dosing and $34,600 with every-other-month (EOM) dosing, and costs per quality-adjusted life-year (QALY) gained, based on modeled visual loss with 95% atrophy, of $706,000 (EM) and $397,000 (EOM). A second analysis based on 2022 Medicare reimbursement data reported 2-year costs of $67,400 (EM) and $40,600 (EOM) for avacincaptad pegol; for extrafoveal geographic atrophy, the facility-based cost per mm2 of retinal pigment epithelium saved was $119,000 (EM) and $57,100 (EOM) with avacincaptad pegol versus $54,000 (EM) and $31,400 (EOM) with pegcetacoplan (P < 0.001 for both comparisons). A de novo U.S. cost-utility model of pegcetacoplan that included the costs and utility loss of informal caregiving reported $77,735 per QALY gained over a lifetime with costs and benefits discounted at 3.5%, and $55,806 per QALY gained for lesions at least 250 μm from the foveal center.

In Australia, the Pharmaceutical Benefits Advisory Committee (PBAC) assessed cost-utility analyses of both products versus best supportive care over 20 years. For pegcetacoplan, multivariate analyses increased the base case ICER from $45,000 to < $55,000 to $95,000 to < $115,000 per QALY gained; the PBAC considered an ICER in the order of $55,000 to < $75,000 per QALY gained acceptable, stated that a price reduction would be required, and considered the amended financial estimates reasonable “as the basis of a risk sharing arrangement”. For avacincaptad pegol, a multivariate analysis increased the base case ICER from $55,000 to < $75,000 to $115,000 to < $135,000 per QALY gained; the PBAC considered an ICER in the order of $45,000 to < $55,000 per QALY gained acceptable, noted that a price reduction would be required, and advised a cost-minimisation approach against pegcetacoplan should pegcetacoplan proceed to listing.

The PBAC financial estimates for pegcetacoplan were a cost to the PBS/RPBS of $50 million to < $60 million in year 6 and $200 million to < $300 million over the first 6 years of listing. For avacincaptad pegol, the submission estimated $20 million to < $30 million in year 1, increasing to $60 million to < $70 million in year 6, and $300 million to < $400 million over the first 6 years; in scenario analyses of continued monthly dosing after year 1, the ESC noted that the year 6 estimate increased to $70 million to < $80 million. The NICE appraisal of pegcetacoplan was suspended after information provided by the company in February 2025 and has been discontinued.

Source: [Patel et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/37572871/); [Patel et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38777140/); [Cummings Joyner et al. (2023)](https://www.ispor.org/heor-resources/presentations-database/presentation/euro2023-3788/133629); [Pharmaceutical Benefits Advisory Committee pegcetacoplan (2025)](https://www.pbs.gov.au/industry/pbac/psd/2025/11/pegcetacoplan-psd-november-2025.pdf?variant=3); [Pharmaceutical Benefits Advisory Committee avacincaptad pegol (2026)](https://www.pbs.gov.au/industry/pbac/psd/2026/03/avacincaptad-pegol-psd-march-2026-a1151.pdf?variant=3); [National Institute for Health and Care Excellence pegcetacoplan appraisal (2026)](https://www.nice.org.uk/guidance/discontinued/gid-ta11351)

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

- Development and regulatory status: vonaprument is investigational, and the sponsor states that it does not “have any products approved for sale”. The FDA has granted Fast Track designation and the EMA PRIME designation for geographic atrophy. The sham-controlled, double-masked phase 3 ARCHER II trial, ongoing in 659 participants, is the planned basis for both an EU filing (single study) and a U.S. filing (two pre-defined sub-studies). As of the sponsor's third-quarter 2026 results release, ARCHER II has reported no efficacy or safety results; the sponsor expects a Data Monitoring Committee assessment of the Month 15 primary endpoint in the fourth quarter of 2026, sub-study results in the first quarter of 2027 if that endpoint is met, and completion with the Month 24 analyses in the third quarter of 2027. The Form 10-Q states that “there is no assurance that either timepoint will show a statistically significant treatment effect”.
- Clinical evidence and its limits: the efficacy evidence comes from one phase 2 trial, ARCHER, in 270 participants treated for 12 months. Its primary endpoint, the rate of change in GA lesion area at month 12, was not met (reductions of 6.2% with monthly dosing, p=0.526, and 1.3% with every-other-month dosing, p=0.896). The visual acuity finding is from a prespecified secondary analysis: BCVA loss of 15 or more letters occurred in 5 of 89 participants (5.6%) with monthly dosing and 19 of 89 (21.3%) with sham (p=0.0021), which the Form 10-K describes as “nominally statistically significant”; the registry reports 4 and 15 events under its definition of loss at 2 consecutive visits. After treatment stopped, the rate of BCVA ≥15-letter loss in the treated groups increased to parallel that of sham. No peer-reviewed publication reports ARCHER results, and a 2026 systematic review excluded them from its evidence synthesis for that reason.
- Safety observed in ARCHER: serious adverse events occurred in 21 of 89 participants (23.60%) with monthly dosing, 16 of 92 (17.39%) with every-other-month dosing, and 16 of 89 (17.98%) with sham. Three serious events of endophthalmitis in treated participants were attributed to the injection procedure; intraocular inflammation occurred in 2 (2.2%) and 1 (1.1%) treated participants and none with sham, and one retinal vascular occlusion (1.1%) occurred with every-other-month dosing. No retinal vasculitis or ischemic optic neuropathy was reported, and choroidal neovascularization occurred in 4.5%, 4.3%, and 3.4% of participants (monthly, every other month, sham).
- Position relative to the approved complement inhibitors: no trial has compared vonaprument with pegcetacoplan or avacincaptad pegol, and in 2025 the sponsor stated that it “no longer plans to conduct a second injection-controlled head-to-head Phase 3 trial”. Pegcetacoplan and avacincaptad pegol were approved on a reduction in the rate of GA expansion, with phase 3 functional data that “demonstrated no visual benefit”; ARCHER II instead uses BCVA ≥15-letter loss as its primary endpoint. The sponsor states that the two approved products “may pose competition for vonaprument, if approved”.
- Unknowns for budget purposes: no price, wholesale acquisition cost, average sales price, or HCPCS code for vonaprument has been published, and no cost-effectiveness analysis, budget impact model, or health technology assessment of vonaprument was identified. The sponsor states that there is no assurance that a product “will be considered cost-effective by third-party payors”.

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm); [Annexon Biosciences third-quarter 2026 results press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-third-quarter-2026-financial-results-business); [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results); [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic); [Vakharia (2025)](https://annexonbio.com/wp-content/uploads/2025/05/Vakharia-RWC-2025-NNT.pdf); [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm); [Annexon Biosciences ASRS 2023 press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-presents-archer-trial-results-asrs-2023-highlighting); [Fernández-Muro et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13708414/); [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c); [Annexon Biosciences fourth-quarter 2024 results press release (2025)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-fourth-quarter-and-year-end-2024-financial); [Csaky et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11162935/)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
